Thyroid Eye Disease Therapy: Insights from Viridian Therapeutics’ THRIVE-2 Trial

By João L. Carapinha

January 6, 2025

Welcome to 2025 and Syenza News, where the first two weeks of January are dedicated to Thyroid Awareness. This period focuses on highlighting advancements in thyroid care, especially chronic thyroid eye disease (TED) and the experimental treatment veligrotug (for thyroid eye disease therapy). Discussions will cover new technologies, their economic impact, outcomes research, and access throughout these two weeks.

Analysis of Viridian Therapeutics’ Announcement on Veligrotug

Viridian Therapeutics recently announced positive results from their Phase 3 THRIVE-2 clinical trial of veligrotug for chronic thyroid eye disease.

Key Findings of the THRIVE-2 Trial

Trial Design and Enrollment: The THRIVE-2 trial is a randomized, double-masked, placebo-controlled study with 188 patients. 125 received veligrotug and 63 received a placebo, with treatments administered three weeks apart.

Efficacy Outcomes: The trial successfully met all primary and secondary endpoints at the 15-week primary analysis timepoint. Veligrotug demonstrated statistically significant improvements in key disease endpoints, including:
– Proptosis: Patients treated with veligrotug achieved a Proptosis Responder Rate (PRR) of 56%. Just 8% of patients on placebo achieved the outcome. The mean reduction in proptosis was 2.34mm from baseline in the veligrotug group, versus 0.46mm in the placebo group.
– Diplopia: Among patients treated with veligrotug, 56% showed a response in diplopia. 32% achieving complete resolution compared to 25% and 14% in the placebo group, respectively.
– Clinical Activity Score (CAS): 54% of veligrotug patients achieved a maximal or near-maximal therapeutic effect on CAS. Researchers defined a maximal or near-maximal therapeutic effect on CAS as reaching a score of 0 or 1, contrasting it with 24% of patients in the placebo group. The mean reduction in CAS was 2.9 from baseline for veligrotug patients, compared to 1.3 for placebo patients.

Safety Profile: Researchers found that veligrotug was well-tolerated and matched the safety profile of earlier studies. There was a low incidence of hearing impairment – 12.8% vs. 3.2% in the placebo group.

Implications and Future Plans

Treatment Potential: The promising results from the THRIVE trials suggest veligrotug could become the preferred treatment for all types of active and chronic TED.

Future Clinical Trials: Viridian Therapeutics is running two global Phase 3 trials, REVEAL-1 and REVEAL-2, for VRDN-003, a new veligrotug formulation. Viridian Therapeutics expects topline results from the Phase 3 trials by mid-2026 and plans to submit a Biologics License Application by late 2026.

Conclusion

THRIVE-2 trial results show significant progress in treating chronic thyroid eye disease, offering new hope and emphasizing the importance of continued research in thyroid care.

Reference url

Recent Posts

NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...